Arcturus Therapeutics Holdings (ARCT) Invested Capital (2020 - 2023)

Arcturus Therapeutics Holdings' Invested Capital history runs 4 years deep, the most recent figure standing at $3.5 million for Q3 2023.

• Quarterly Invested Capital fell 87.39% year-over-year to $3.5 million in Q3 2023, while the trailing twelve-month figure through Jun 2024 was $3.5 million (down 90.07% YoY) and the FY2022 annual result came in at $7.5 million, down 66.77% from the prior year.
• Invested Capital was $3.5 million for Q3 2023 at Arcturus Therapeutics Holdings, down from $7.5 million in the prior quarter.
• Across five years, Invested Capital topped out at $27.7 million in Q3 2022 and bottomed at $1.2 million in Q4 2020.
• A 4-year average of $14.0 million and a median of $13.0 million in 2021 frame the typical range for Invested Capital.
• Annual changes were most pronounced in 2021 — Invested Capital jumped 1697.92% — and 2023, when it plunged 87.39%.
• Arcturus Therapeutics Holdings' Invested Capital stood at $1.2 million in 2020, then soared by 1697.92% to $22.5 million in 2021, then sank by 66.77% to $7.5 million in 2022, then plunged by 53.24% to $3.5 million in 2023.
• Business Quant data shows ARCT's Invested Capital at $3.5 million in Q3 2023, $7.5 million in Q4 2022, and $27.7 million in Q3 2022.